Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
March Against Monsanto from their land while conserving resources, such as water and energy. The company reiterated that genetically engineered foods were safe and improved crop yields. Similar sentiments were expressed by the Hawaii Crop Improvement Association, of which Monsanto is a member. A second protest was organized and held on October 12, 2013. The group Occupy Monsanto estimated that over 400 marches were held worldwide, with other reports estimating participation at 500 events in 50 different countries. The October march was scheduled to coincide with World Food Day, and came after Monsanto executives had been awarded the World Food Prize; the Des